Editorial: Chrononutrition and MASLD—It is About Time (Restricted Feeding)! Authors' Reply DOI Open Access
Sofia Tsitsou,

Magdalini Adamantou,

Triada Bali

и другие.

Alimentary Pharmacology & Therapeutics, Год журнала: 2025, Номер unknown

Опубликована: Март 26, 2025

We sincerely appreciate the opportunity to respond editorial by Mohr and Stine discussing our study on effects of a 12-week Mediterranean-type time-restricted feeding (TRF) protocol in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) [1, 2]. are grateful for their insightful commentary highlighting strengths randomised controlled trial (RCT). Their analysis underscores emerging role chrononutrition managing MASLD while also key questions regarding independent contribution TRF caloric restriction improvements. There is indeed great need studies that directly compare ad libitum protocols evaluate differentiative impact several parameters. Most have compared either usual dietary habits participants or hypocaloric diets both control groups, as study. Our was first RCT used Mediterranean Diet (MD) group, gold standard [3]. The MD has been extensively documented an effective intervention [4]. adds this body evidence demonstrating MD, even over short-term period, yields significant improvements weight, fat, blood pressure fat content [1]. Regarding comment generalizability results [2], it true Greece country, described previous studies, Greeks' adherence moderate [5]. [1] agree these [5] may enhanced participants' adherence. interventions (early late) did not seem improve parameters mentioned above further population However, insulin resistance haemoglobin A1c (HbA1c) were only improved early but late group. reduction HbA1c group (0.3% total, 0.37% those T2DM under TRF) greater than other similar example, 0.2% Wei et al. + group) [6], whilst grade improvement associated lower mortality individuals [7] diabetic complications [8]. Prior suggest aligning food intake circadian rhythms light/dark cycle via enhance glucose metabolism humans diurnal [9]. This particularly relevant patients, where pivotal driver progression [10]. That means differences observed probably due intervention, all groups had same restriction. would like thank authors thoughtful comments, which allowed us refine interpretation highlight robustness findings. Future research will provide answers raised concerns. Sofia Tsitsou: writing – original draft, investigation, methodology, data curation. Magdalini Adamantou: curation, investigation. Triada Bali: Aristi Saridaki: Kalliopi-Anna Poulia: methodology. Dimitrios S. Karagiannakis: Emilia Papakonstantinou: Evangelos Cholongitas: conceptualization, review editing, project administration, supervision, visualization, draft. declare no conflicts interest. article linked Tsitsou al papers. To view articles, visit https://doi.org/10.1111/apt.70044 https://doi.org/10.1111/apt.70078. support findings available request from corresponding author. publicly privacy ethical restrictions.

Язык: Английский

Editorial: Chrononutrition and MASLD—Its About Time (Restricted Feeding)! DOI Open Access

Hans-Jürgen Mohr,

Jonathan G. Stine

Alimentary Pharmacology & Therapeutics, Год журнала: 2025, Номер unknown

Опубликована: Март 26, 2025

The global obesity epidemic and the widespread adoption of a Westernised diet high in sugar processed foods, alongside sedentary lifestyle, have fueled rise metabolic dysfunction-associated steatotic liver disease (MASLD) [1]. Since an unhealthy lifestyle is central to MASLD development, effective interventions remain essential for improving patient outcomes [2]. Mediterranean (MD), rich produce, whole grains healthy fats like olive oil, while limiting red meat widely recognized as key dietary intervention [3, 4]. Adherence MD has shown reduction hepatic fat, improved insulin sensitivity, slowed progression [5, 6]. However, barriers such cost, accessibility, cultural preferences hinder adoption. As result, alternative strategies, time-restricted feeding (TRF), gained attention. TRF limits food intake set daily window, typically 6 10 h, followed by fasting. Although demonstrated health benefits, particularly when paired with caloric restriction [7], its optimal implementation impact on unclear, it not yet considered standard care. In CHRONO-NAFLD study, Tsitsou et al. [8] explored efficacy + combination. 12-week trial randomized 71 adults overweight/obesity into three groups: hypocaloric (control), early (8 AM–6 PM), late (12 PM–10 PM). Dietary adherence was rigorously measured using self-reports verified study personnel reinforced via phone calls, > 90% each group. boasted completion rate 83%. All groups experienced significant reductions body weight, blood pressure, along improvements VCTE-measured fat modest trend toward reduced stiffness. Notably, only between-group differences emerged glycemic control, resistance hemoglobin A1c observed both groups. these changes, statistically significant, did reach clinically meaningful thresholds (Figure 1). Importantly, this several strengths, including well-characterized population, rigorous methodology, validated measures assessing multiple relevant outcomes. limitations include selection bias (84% participants had moderate at baseline) most were physically active (> 600 MET-min/week). This generalisability, cohort relatively homogenous inclined consumption. Key confounders, meal composition physical activity also fully controlled. design precluded distinguishing whether benefits stemmed from itself or restriction. summary, shows promise control. further studies are needed determine if independently improves histology long-term questions due fasting simply intake, sustainable over time. While appears safe feasible, remains unclear offers advantages other structured calorically matched. Hannah Mohr: writing – original draft, review editing. Jonathan G. Stine: conceptualization, content solely responsibility authors does necessarily represent official views National Institutes Health. AI-based software used grammatical stylistic editing various parts manuscript. Dr. Stine receives received research support Astra Zeneca, Galectin, Kowa Inc., Novo Nordisk, Regeneron Zydus Therapeutics. consults Nordisk Advisory Board Madrigal. declare no conflicts interest. article linked al papers. To view articles, visit https://doi.org/10.1111/apt.70044 https://doi.org/10.1111/apt.70107. Data sharing applicable datasets generated analysed during current study.

Язык: Английский

Процитировано

1
Editorial: Chrononutrition and MASLD—It is About Time (Restricted Feeding)! Authors' Reply DOI Open Access
Sofia Tsitsou,

Magdalini Adamantou,

Triada Bali

и другие.

Alimentary Pharmacology & Therapeutics, Год журнала: 2025, Номер unknown

Опубликована: Март 26, 2025

We sincerely appreciate the opportunity to respond editorial by Mohr and Stine discussing our study on effects of a 12-week Mediterranean-type time-restricted feeding (TRF) protocol in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) [1, 2]. are grateful for their insightful commentary highlighting strengths randomised controlled trial (RCT). Their analysis underscores emerging role chrononutrition managing MASLD while also key questions regarding independent contribution TRF caloric restriction improvements. There is indeed great need studies that directly compare ad libitum protocols evaluate differentiative impact several parameters. Most have compared either usual dietary habits participants or hypocaloric diets both control groups, as study. Our was first RCT used Mediterranean Diet (MD) group, gold standard [3]. The MD has been extensively documented an effective intervention [4]. adds this body evidence demonstrating MD, even over short-term period, yields significant improvements weight, fat, blood pressure fat content [1]. Regarding comment generalizability results [2], it true Greece country, described previous studies, Greeks' adherence moderate [5]. [1] agree these [5] may enhanced participants' adherence. interventions (early late) did not seem improve parameters mentioned above further population However, insulin resistance haemoglobin A1c (HbA1c) were only improved early but late group. reduction HbA1c group (0.3% total, 0.37% those T2DM under TRF) greater than other similar example, 0.2% Wei et al. + group) [6], whilst grade improvement associated lower mortality individuals [7] diabetic complications [8]. Prior suggest aligning food intake circadian rhythms light/dark cycle via enhance glucose metabolism humans diurnal [9]. This particularly relevant patients, where pivotal driver progression [10]. That means differences observed probably due intervention, all groups had same restriction. would like thank authors thoughtful comments, which allowed us refine interpretation highlight robustness findings. Future research will provide answers raised concerns. Sofia Tsitsou: writing – original draft, investigation, methodology, data curation. Magdalini Adamantou: curation, investigation. Triada Bali: Aristi Saridaki: Kalliopi-Anna Poulia: methodology. Dimitrios S. Karagiannakis: Emilia Papakonstantinou: Evangelos Cholongitas: conceptualization, review editing, project administration, supervision, visualization, draft. declare no conflicts interest. article linked Tsitsou al papers. To view articles, visit https://doi.org/10.1111/apt.70044 https://doi.org/10.1111/apt.70078. support findings available request from corresponding author. publicly privacy ethical restrictions.

Язык: Английский

Процитировано

0